US Stock MarketDetailed Quotes
PROK ProKidney
- 2.100
- -0.010-0.47%
Trading Jul 22 11:02 ET
242.33MMarket Cap-3684P/E (TTM)
2.130High2.020Low135.18KVolume2.110Open2.110Pre Close279.11KTurnover0.19%Turnover RatioLossP/E (Static)115.40MShares13.51052wk High-0.22P/B147.47MFloat Cap1.12052wk Low--Dividend TTM70.22MShs Float14.190Historical High--Div YieldTTM5.21%Amplitude1.120Historical Low2.064Avg Price1Lot Size
ProKidney Stock Forum
Sign in to post a comment
$ProKidney(PROK.US$ ProKidney Announces the Closing of $140 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
2
$ProKidney(PROK.US$
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2
$ProKidney(PROK.US$ ProKidney Announces Proposed $125 Million Public Offering of Class a Ordinary Shares and Concurrent Registered Direct Offering
$ProKidney(PROK.US$ Reuters
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
3
$ProKidney(PROK.US$
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
Wall Street's meme-stock madness extended to more companies Tuesday, with $ProKidney(PROK.US$ and other names rising more than 25% despite no apparent news.
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
7
2
$ProKidney(PROK.US$ sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
7
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
MARKET-TEST-DUMMY : With closings of offering and exercise of option do you anticipate with insider sell there being a drop before an uptick occurs?
TrytosaveabitOP MARKET-TEST-DUMMY: It’s hard to tell just yet! But the big drop that comes with a offering should be well over! Now it will more than likely be shorts ifn it drops much?